Form 8-K - Current report:
SEC Accession No. 0001628280-24-051956
Filing Date
2024-12-19
Accepted
2024-12-19 08:02:50
Documents
19
Period of Report
2024-12-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20241219.htm   iXBRL 8-K 28465
2 EX-99.1 aqstorphandrugdesignatio.htm EX-99.1 16874
6 aqstorphandrugdesignatio001.jpg GRAPHIC 277066
7 aqstorphandrugdesignatio002.jpg GRAPHIC 240149
8 aqstorphandrugdesignatio003.jpg GRAPHIC 197304
9 aqstorphandrugdesignatio004.jpg GRAPHIC 280052
10 aqstorphandrugdesignatio005.jpg GRAPHIC 148053
  Complete submission text file 0001628280-24-051956.txt   1749881

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20241219.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20241219_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20241219_pre.xml EX-101.PRE 12504
21 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20241219_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 241561017
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)